UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGNPRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026.

Commission File Number: 001-40627

SOPHiA GENETICS SA

(Exact name of registrant as specified in itscharter)

La Pièce 12

CH-1180 Rolle

Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant filesor will file annual reports under cover of Form 20-F or Form 40-F:

On January 12, 2026, SOPHiA GENETICS SA (the “Company”)announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026. Mr. Muken, who currently serves as Presidentand has been a key executive at the company for five years, will succeed Dr. Jurgi Camblong, co-founder and CEO. Dr. Camblong will transitionto Executive Chairman of the Board, subject to election at the Company’s Annual General Meeting in June 2026.

In addition, the Company announced certain preliminaryunaudited financial results for the quarter and the year ended December 31, 2025. For the quarter ended December 31, 2025, the Companyexpects to report revenue of at least $21 million, representing an increase of approximately 20% year-over-year, and the Company performedover 105,000 analyses on SOPHiA DDM, representing 16% year-over-year growth. For the year ended December 31, 2025, the Company expectsto report revenue of approximately $77 million, representing an increase of approximately 18% year-over-year, and the Company performedover 391,000 analyses on SOPHiA DDM, a new company record. The Company has not completed preparation of its financial statements for thequarter and the year ended December 31, 2025. The estimates presented in this Form 6-K for the quarter and year ended December 31, 2025are preliminary and unaudited and are thus inherently uncertain and subject to change as the Company completes its financial results forthe fourth quarter of 2025. The Company is in the process of completing its customary year-end close and review procedures as of and forthe year ended December 31, 2025, and there can be no assurance that final results for this period will not differ from these estimates.During the course of the preparation of the Company’s consolidated financial statements and related notes as of and for the yearended December 31, 2025, the Company may identify items that could cause final reported results to be materially different from the preliminaryfinancial estimates presented herein. The Company’s independent registered public accountants do not express any opinion regardingthe preliminary financial estimates presented herein.

INCORPORATION BY REFERENCE

This Report on Form 6-K shall be deemed to be incorporatedby reference into the registration statements on Form F-3 (Registration Nos. 333-280060, 333-289266 and 333-289270) of SOPHiA GENETICSSA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequentlyfiled or furnished.

SIGNATURE

Pursuant to therequirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,thereunto duly authorized.